aspirin has been researched along with Hemorrhagic Thrombocythemia in 186 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of aspirin in the antithrombotic strategy of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is highly controversial." | 10.18 | Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. ( Landolfi, R; Patrono, C, 1996) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 8.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 7.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "The effectiveness of low-dose aspirin in the primary prevention of thrombosis in patients with high-risk essential thrombocythaemia (ET) treated with cytoreductive drugs is not well established." | 7.79 | Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. ( Alvarez-Larrán, A; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Hernández-Boluda, JC; Pereira, A, 2013) |
| "The role of aspirin in the antithrombotic strategy of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is highly controversial." | 6.18 | Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. ( Landolfi, R; Patrono, C, 1996) |
| "Essential thrombocythemia is a rare disease of unknown origin characterized by abnormal increase in the platelet count." | 5.32 | Pregnancy in essential thrombocythemia during aspirin treatment. ( Cannata, ML; Corrado, F; Ruggeri, Z; Stella, NC, 2003) |
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract." | 4.83 | Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 4.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 3.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "The effectiveness of low-dose aspirin in the primary prevention of thrombosis in patients with high-risk essential thrombocythaemia (ET) treated with cytoreductive drugs is not well established." | 3.79 | Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. ( Alvarez-Larrán, A; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Hernández-Boluda, JC; Pereira, A, 2013) |
| "All the patients were treated with low dose aspirin during the pregnancy." | 3.77 | [Pregnancy and essential thrombocytemia]. ( Cambier, N; Depret, S; Deruelle, P; Ducloy, AS; Giraudet, G; Houfflin-Debarge, V; Vaast, P; Wibaut, B, 2011) |
| " Erythromelalgia is causally related to thrombocythaemia; prompt relief of painful symptoms after treatment with aspirin is typical." | 3.69 | [Cutaneous manifestations of essential thrombocythemia. Erythromelalgia, ischemic acrocyanosis, livedo racemosa]. ( Bauerschmitz, J; Knop, J, 1995) |
| " The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement with further reductions (EudraCT 2016-002885-30)." | 2.94 | A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. ( Beggiato, E; Bertozzi, I; Betti, S; Bucelli, C; Carli, G; Carpenedo, M; Cattaneo, D; Cavalca, V; De Stefano, V; Di Ianni, M; Dragani, A; Elli, EM; Iurlo, A; Lanzarone, G; Palandri, F; Paoli, C; Patrono, C; Petrucci, G; Porro, B; Ranalli, P; Randi, ML; Ricco, A; Rocca, B; Rodeghiero, F; Rossi, E; Ruggeri, M; Soldati, D; Specchia, G; Timillero, A; Tosetto, A; Vannucchi, AM; Vianelli, N, 2020) |
| " A twice daily (bid) dosing is necessary to fully inhibit TXA2." | 2.79 | In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. ( Barbieri, SS; Cavalca, V; Dragani, A; Pagliaccia, F; Patrono, C; Porro, B; Rocca, B; Squellerio, I; Tremoli, E; Veglia, F, 2014) |
| " In the present study, we investigated the determinants of aspirin-insensitive platelet TXA(2) biosynthesis and whether it could be further suppressed by changing the aspirin dose, formulation, or dosing interval." | 2.77 | Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. ( Dragani, A; Habib, A; Pagliaccia, F; Pascale, S; Patrono, C; Petrucci, G; Pocaterra, D; Ragazzoni, E; Rocca, B; Rolandi, G; Zaccardi, F, 2012) |
| "Aspirin was fully efficient in only 30% of cases." | 2.76 | Neurological disorders in essential thrombocythemia. ( Billot, S; Carpentier, AF; Cassinat, B; Fenaux, P; Jardin, C; Kiladjian, JJ; Kouroupi, EG; Laperche, T; Le Guilloux, J, 2011) |
| "Essential thrombocythemia is associated with an increased risk of thromboembolic complications." | 2.74 | The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. ( Chojnowski, K; Robak, T; Smolewski, P; Treliński, J; Tybura, M, 2009) |
| "Pregnancy is not contraindicated in MPNs, and we recommend aspirin throughout pregnancy with consideration for prophylactic postpartum anticoagulation." | 2.72 | Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. ( Hobbs, G; How, J, 2021) |
| "The priapism was managed with repeated aspiration and instillation of phenylephrine." | 2.66 | Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature. ( Jain, M; Kumar, N; Tripathi, AK; Verma, SP, 2020) |
| "Controlled studies are needed to confirm the clinical outcome value of twice-daily vs once-daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants." | 2.66 | Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2020) |
| " Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events." | 2.58 | Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review. ( Hasegawa, M; Sakai, K; Ueda, A; Ueda, Y, 2018) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Because of the rarity of primary thrombocythemia thus far only two prospectively randomized studies have been carried out to compare cyto- and thromboreductive therapies." | 2.43 | [Primary thrombocythemia: diagnosis and therapy]. ( Petrides, PE, 2006) |
| "Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders." | 2.42 | Essential thrombocythemia. ( Green, AR; Harrison, CN, 2003) |
| "The striking similarity to migraine, together with the absence of vascular risk factors and the striking efficacy of aspirin treatment supports the hypothesis that the ischemic neurologic and visual symptoms in ET are caused by shear rate-induced intravascular activation and aggregation of platelets with subsequent transient sludging or occlusion of the cerebral arterial microvasculature." | 2.40 | Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997) |
| "Essential thrombocythemia is a chronic myeloproliferative disease characterized by persistent thrombocytosis and an increased risk of thromboembolic complications." | 2.40 | [A management program for primary thrombocytopenia]. ( Bruserud, O; Knutsen, H, 1999) |
| "Essential thrombocythemia is a myeloproliferative disorder characterized by a persistent increase in the platelet count." | 2.40 | Essential thrombocythemia during pregnancy. ( Eliyahu, S; Shalev, E, 1997) |
| "Placental infarction due to thrombosis seems to be the most consistent pathological event as far as the fetus is concerned." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "One pregnancy was complicated by superficial thrombophlebitis and a postpartum haemorrhage." | 2.38 | Primary thrombocythaemia in pregnancy. ( Anderson, CC; Beard, J; Hillmen, P; Lewis, SM; Pearson, TC, 1991) |
| "A computational approach involving mathematical modeling and in silico experiments was used to characterize the determinants of extent and duration of platelet cyclooxygenase (COX)-1 inhibition by aspirin and design precision dosing in patients with accelerated platelet turnover or reduced drug bioavailability." | 1.72 | Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing. ( Giaretta, A; Petrucci, G; Rocca, B; Toffolo, GM, 2022) |
| "Nine pregnancies ended in miscarriages (9/34; 26." | 1.62 | Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. ( Becker, T; Griesshammer, M; Heidel, FH; Hochhaus, A; Kolatzki, V; Sadjadian, P; Schrickel, L; Wille, K, 2021) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Essential thrombocythemia is characterized by persistent elevation and functional disturbances of platelets." | 1.37 | Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia. ( Chondropoulos, S; Dervenoulas, J; Kapsimali, V; Kopterides, P; Mantzios, G; Nikolopoulos, GK; Tsantes, AE; Tsirigotis, P; Zoi, K; Zomas, A, 2011) |
| "Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics." | 1.35 | Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies. ( Niazi, M; Robins, EB, 2008) |
| "We report a case of ET and chronic renal failure treated with anagrelide and low-dose aspirin in a patient who did not receive transfusion and surgical intervention due to religious reasons, and had a fatal outcome." | 1.35 | Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. ( Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB, 2009) |
| "21/29, 72." | 1.35 | Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. ( Candoni, A; Cascavilla, N; Cedrone, M; Ciancia, R; Comitini, G; Gugliotta, L; Latagliata, R; Martinelli, V; Martino, B; Melillo, L; Palmieri, F; Radaelli, F; Scalzulli, PR; Specchia, G; Tieghi, A; Usala, E; Valente, D; Valvano, MR, 2009) |
| "Furthermore, the occurrence of a miscarriage in ET might be a marker for a similar event during subsequent pregnancies." | 1.35 | Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. ( Gangat, N; Schwager, S; Tefferi, A; Wolanskyj, AP, 2009) |
| "Essential thrombocythemia is a rare disease of unknown origin characterized by abnormal increase in the platelet count." | 1.32 | Pregnancy in essential thrombocythemia during aspirin treatment. ( Cannata, ML; Corrado, F; Ruggeri, Z; Stella, NC, 2003) |
| "Management of ET in pregnancy is still very much individualized." | 1.31 | Four pregnancies in two patients with essential thrombocythaemia--a case report. ( Devendra, K; Koh, LP; Tien, SL, 2002) |
| "Hydroxyurea was given to patients with ET with a positive history for major vascular complications or with an extreme thrombocytosis." | 1.30 | Acute coronary disease in essential thrombocythemia and polycythemia vera. ( Girolami, A; Randi, ML; Rinaldi, V; Rossi, C; Zerbinati, P, 1998) |
| "Treatment with aspirin inhibited spontaneous platelet aggregation but had little effect on the activated platelet profile." | 1.29 | Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. ( Bihour, C; Nurden, AT; Nurden, P; Raymond, JM; Smith, M, 1996) |
| "A 59-year-old man had central retinal vein occlusion in the left eye as the initial sign of essential thrombocythemia." | 1.29 | Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma. ( Townsend-Pico, W; Yoshizumi, MO, 1996) |
| "Aspirin was prescribed for the next 2 years at varying doses and frequency." | 1.28 | Essential thrombocythemia in a child: management with anagrelide. ( Chintagumpala, MM; Fernbach, DJ; Mahoney, DH; Ogden, AK; Steuber, CP, 1991) |
| "Primary thrombocythemia is a myeloproliferative disease characterized by a sustained and marked increase in platelet count." | 1.27 | [Primary thrombocythemia in childhood]. ( de Vaan, G; Flapper, B; Van Oostrom, C, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (6.99) | 18.7374 |
| 1990's | 39 (20.97) | 18.2507 |
| 2000's | 54 (29.03) | 29.6817 |
| 2010's | 51 (27.42) | 24.3611 |
| 2020's | 29 (15.59) | 2.80 |
| Authors | Studies |
|---|---|
| How, J | 1 |
| Hobbs, G | 1 |
| Tosetto, A | 3 |
| Rocca, B | 8 |
| Petrucci, G | 7 |
| Betti, S | 4 |
| Soldati, D | 3 |
| Rossi, E | 3 |
| Timillero, A | 3 |
| Cavalca, V | 4 |
| Porro, B | 3 |
| Iurlo, A | 3 |
| Cattaneo, D | 3 |
| Bucelli, C | 2 |
| Dragani, A | 7 |
| Di Ianni, M | 2 |
| Ranalli, P | 4 |
| Palandri, F | 3 |
| Vianelli, N | 3 |
| Beggiato, E | 3 |
| Lanzarone, G | 3 |
| Ruggeri, M | 4 |
| Carli, G | 3 |
| Elli, EM | 2 |
| Priolo, S | 1 |
| Randi, ML | 12 |
| Bertozzi, I | 5 |
| Loscocco, GG | 2 |
| Ricco, A | 3 |
| Specchia, G | 4 |
| Vannucchi, AM | 7 |
| Rodeghiero, F | 4 |
| De Stefano, V | 4 |
| Patrono, C | 8 |
| Goulart, H | 1 |
| Mascarenhas, J | 1 |
| Tremblay, D | 1 |
| Edahiro, Y | 1 |
| Kishi, Y | 1 |
| Aota, Y | 1 |
| Horie, Y | 1 |
| Sutoh, A | 1 |
| Moriyama, M | 1 |
| Okabe, M | 1 |
| Iguchi, T | 1 |
| Yokouchi, Y | 1 |
| Gotoh, A | 1 |
| Maetani, I | 1 |
| Nicol, C | 1 |
| Ajzenberg, N | 1 |
| Lacut, K | 1 |
| Couturaud, F | 1 |
| Lippert, E | 2 |
| Pan-Petesch, B | 1 |
| Ianotto, JC | 4 |
| Pedersen, OB | 1 |
| Grove, EL | 1 |
| Pasalic, L | 1 |
| Ommen, HB | 1 |
| Kristensen, SD | 1 |
| Hvas, AM | 1 |
| Stuckey, R | 1 |
| Santoro, M | 1 |
| Czyż, A | 1 |
| Perez Encinas, MM | 1 |
| Gómez-Casares, MT | 1 |
| Noya Pereira, MS | 1 |
| de Nałęcz, AK | 1 |
| Gołos, A | 1 |
| Lewandowski, K | 1 |
| Szukalski, Ł | 1 |
| González-Martín, JM | 1 |
| Wróbel, T | 1 |
| Sobas, MA | 1 |
| Giaretta, A | 1 |
| Toffolo, GM | 1 |
| Cattaneo, M | 2 |
| Khodier, M | 1 |
| Gadó, K | 1 |
| Tefferi, A | 20 |
| Pardanani, A | 3 |
| Arimura, A | 1 |
| Fujii, K | 1 |
| Hayashida, M | 1 |
| Higashi, Y | 1 |
| Hashiguchi, T | 1 |
| Kanekura, T | 1 |
| Fleischman, RA | 1 |
| Rumi, E | 3 |
| Cazzola, M | 2 |
| Carpenedo, M | 2 |
| Paoli, C | 2 |
| Bolaman, AZ | 1 |
| Yavaşoǧlu, İ | 2 |
| Kellner, A | 1 |
| Dombi, P | 2 |
| Illes, A | 2 |
| Demeter, J | 2 |
| Homor, L | 2 |
| Ercsei, I | 1 |
| Simon, Z | 2 |
| Karadi, E | 2 |
| Herczeg, J | 1 |
| Gy Korom, V | 1 |
| Gasztonyi, Z | 1 |
| Szerafin, L | 1 |
| Udvardy, M | 2 |
| Egyed, M | 2 |
| Rebière, V | 1 |
| Tudesq, JJ | 1 |
| Chauveau, A | 2 |
| Eveillard, JR | 1 |
| Darmon, M | 1 |
| Braunstein, EM | 1 |
| Chaturvedi, S | 1 |
| Verma, SP | 1 |
| Kumar, N | 1 |
| Jain, M | 1 |
| Tripathi, AK | 1 |
| Barbui, T | 15 |
| Schrickel, L | 1 |
| Heidel, FH | 1 |
| Sadjadian, P | 1 |
| Becker, T | 1 |
| Kolatzki, V | 1 |
| Hochhaus, A | 1 |
| Griesshammer, M | 8 |
| Wille, K | 1 |
| Xie, J | 1 |
| Geng, L | 1 |
| Yuan, B | 1 |
| Guo, Y | 1 |
| Zhang, Z | 1 |
| Okada, Y | 2 |
| Kimura, F | 1 |
| Scavone, M | 1 |
| Podda, GM | 1 |
| Bossi, E | 1 |
| Paroni, R | 1 |
| Szuber, N | 1 |
| Hanson, CA | 1 |
| Gangat, N | 3 |
| Antonioli, E | 1 |
| Romano, I | 1 |
| Vergoni, F | 1 |
| Rotunno, G | 1 |
| Mannelli, F | 1 |
| Guglielmelli, P | 1 |
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Kempen, PM | 1 |
| Sakai, K | 1 |
| Ueda, A | 1 |
| Hasegawa, M | 1 |
| Ueda, Y | 1 |
| Ventejou, S | 1 |
| Delaplace, M | 1 |
| Dehayes, P | 1 |
| Bailly, E | 1 |
| Machet, L | 1 |
| Elli, E | 2 |
| Finazzi, G | 7 |
| Lissandrini, L | 1 |
| Rambaldi, A | 3 |
| Turnu, L | 1 |
| Godfrey, AL | 1 |
| Campbell, PJ | 2 |
| MacLean, C | 1 |
| Buck, G | 2 |
| Cook, J | 1 |
| Temple, J | 1 |
| Wilkins, BS | 2 |
| Wheatley, K | 2 |
| Nangalia, J | 1 |
| Grinfeld, J | 1 |
| McMullin, MF | 1 |
| Forsyth, C | 1 |
| Kiladjian, JJ | 3 |
| Green, AR | 5 |
| Harrison, CN | 4 |
| Putti, MC | 2 |
| Bain, BJ | 1 |
| Garnett, C | 1 |
| Deplano, S | 1 |
| Naresh, K | 1 |
| Kanfer, E | 1 |
| Alvarez-Larrán, A | 3 |
| Cervantes, F | 2 |
| Besses, C | 3 |
| Pereira, A | 1 |
| Arellano-Rodrigo, E | 1 |
| Hernández-Boluda, JC | 1 |
| Squizzato, A | 2 |
| Romualdi, E | 2 |
| Passamonti, F | 4 |
| Middeldorp, S | 2 |
| Haznedaroglu, IC | 1 |
| Panova-Noeva, M | 1 |
| Marchetti, M | 2 |
| Russo, L | 1 |
| Tartari, CJ | 1 |
| Leuzzi, A | 1 |
| ten Cate, H | 1 |
| Falanga, A | 2 |
| Ling, C | 1 |
| Zhu, GH | 1 |
| Jin, L | 1 |
| Squellerio, I | 1 |
| Veglia, F | 1 |
| Pagliaccia, F | 2 |
| Barbieri, SS | 1 |
| Tremoli, E | 1 |
| Michiels, JJ | 13 |
| Berneman, Z | 3 |
| Gadisseur, A | 1 |
| Lam, KH | 1 |
| De Raeve, H | 1 |
| Schroyens, W | 3 |
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
| Lancellotti, S | 1 |
| Basso, M | 1 |
| Tartaglione, R | 1 |
| De Cristofaro, R | 1 |
| Keohane, C | 1 |
| McLornan, DP | 1 |
| Sanchez, K | 1 |
| Connor, C | 1 |
| Radia, D | 1 |
| Verger, E | 1 |
| Cassinat, B | 2 |
| Dosquet, C | 1 |
| Giraudier, S | 1 |
| Schlageter, MH | 1 |
| Yassin, MA | 1 |
| Al-Dewik, N | 1 |
| Carillo, S | 1 |
| Legouffe, E | 1 |
| Ugo, V | 1 |
| Chomienne, C | 1 |
| Buxhofer-Ausch, V | 1 |
| Gisslinger, H | 2 |
| Carobbio, A | 1 |
| Thiele, J | 1 |
| Falcone, C | 1 |
| Villani, M | 1 |
| Colaizzo, D | 1 |
| Tiscia, GL | 1 |
| Chinni, E | 1 |
| Bodenizza, C | 1 |
| Cascavilla, N | 2 |
| Grandone, E | 1 |
| Sakamoto, Y | 1 |
| Nito, C | 1 |
| Abe, A | 1 |
| Nogami, A | 1 |
| Sato, T | 1 |
| Sawada, K | 1 |
| Hokama, H | 1 |
| Yamada, M | 1 |
| Hijikata, N | 1 |
| Kumagai, T | 1 |
| Ishiwata, A | 1 |
| Nagayama, H | 1 |
| Kimura, K | 1 |
| Shimazu, Y | 1 |
| Fujimura, K | 1 |
| Inoue, S | 1 |
| Okiyama, N | 1 |
| Okune, M | 1 |
| Shiraki, N | 1 |
| Kessoku, R | 1 |
| Fujimoto, M | 1 |
| Piccin, A | 1 |
| Steurer, M | 1 |
| Feistritzer, C | 1 |
| Murphy, C | 1 |
| Eakins, E | 1 |
| Van Schilfgaarde, M | 1 |
| Corvetta, D | 1 |
| Di Pierro, AM | 1 |
| Pusceddu, I | 1 |
| Marcheselli, L | 1 |
| Gambato, R | 1 |
| Langes, M | 1 |
| Veneri, D | 1 |
| Perbellini, O | 1 |
| Pacquola, E | 1 |
| Gottardi, M | 1 |
| Gherlinzoni, F | 1 |
| Mega, A | 1 |
| Tauber, M | 1 |
| Mazzoleni, G | 1 |
| Piva, E | 1 |
| Plebani, M | 1 |
| Krampera, M | 1 |
| Gastl, G | 1 |
| Struve, S | 1 |
| Birgegård, G | 1 |
| Bildirici, U | 1 |
| Celikyurt, U | 1 |
| Ural, E | 1 |
| Wolanskyj, AP | 1 |
| Schwager, S | 1 |
| Estilita, J | 1 |
| Alonso, FM | 1 |
| Brasil, JS | 1 |
| Baptista, MS | 1 |
| Melillo, L | 1 |
| Tieghi, A | 1 |
| Candoni, A | 1 |
| Radaelli, F | 1 |
| Ciancia, R | 1 |
| Martino, B | 1 |
| Scalzulli, PR | 1 |
| Latagliata, R | 1 |
| Palmieri, F | 1 |
| Usala, E | 1 |
| Valente, D | 1 |
| Valvano, MR | 1 |
| Cedrone, M | 1 |
| Comitini, G | 1 |
| Martinelli, V | 1 |
| Gugliotta, L | 1 |
| Kurosawa, H | 1 |
| Okuya, M | 1 |
| Matsushita, T | 1 |
| Kubota, T | 1 |
| Endoh, K | 1 |
| Kuwashima, S | 1 |
| Hagisawa, S | 1 |
| Sato, Y | 1 |
| Fukushima, K | 1 |
| Sugita, K | 1 |
| Park, MJ | 1 |
| Hayashi, Y | 1 |
| Arisaka, O | 1 |
| Treliński, J | 1 |
| Tybura, M | 1 |
| Smolewski, P | 1 |
| Robak, T | 1 |
| Chojnowski, K | 1 |
| Pascale, S | 2 |
| Recchiuti, A | 1 |
| Mattoscio, D | 1 |
| Lattanzio, S | 1 |
| Mucci, L | 1 |
| Ferrante, E | 1 |
| Habib, A | 2 |
| Ranelletti, FO | 1 |
| Ciabattoni, G | 1 |
| Davì, G | 1 |
| Morra, E | 1 |
| Beer, PA | 1 |
| Mesquita, Mdo C | 1 |
| Sol, EB | 1 |
| Malarme, M | 1 |
| Noubouossie, D | 1 |
| Demulder, AC | 1 |
| Robier, C | 1 |
| Neubauer, M | 1 |
| Sternad, H | 1 |
| Quehenberger, F | 1 |
| Rainer, F | 1 |
| Neumeister, P | 1 |
| Harrison, C | 1 |
| Ayvaz, OC | 1 |
| Kadikoylu, G | 1 |
| Bozkurt, G | 1 |
| Bolaman, Z | 1 |
| Giraudet, G | 1 |
| Wibaut, B | 1 |
| Ducloy, AS | 1 |
| Deruelle, P | 1 |
| Depret, S | 1 |
| Cambier, N | 1 |
| Vaast, P | 1 |
| Houfflin-Debarge, V | 1 |
| Tsantes, AE | 1 |
| Nikolopoulos, GK | 1 |
| Tsirigotis, P | 1 |
| Zoi, K | 1 |
| Zomas, A | 1 |
| Kapsimali, V | 1 |
| Kopterides, P | 1 |
| Chondropoulos, S | 1 |
| Dervenoulas, J | 1 |
| Mantzios, G | 1 |
| Billot, S | 1 |
| Kouroupi, EG | 1 |
| Le Guilloux, J | 1 |
| Jardin, C | 1 |
| Laperche, T | 1 |
| Fenaux, P | 1 |
| Carpentier, AF | 1 |
| Dillinger, JG | 1 |
| Sideris, G | 1 |
| Henry, P | 1 |
| Bal dit Sollier, C | 1 |
| Ronez, E | 1 |
| Drouet, L | 1 |
| Belotti, A | 1 |
| Speranza, T | 1 |
| Lanzi, E | 1 |
| Pioltelli, P | 1 |
| Pogliani, E | 1 |
| Zaccardi, F | 1 |
| Pocaterra, D | 1 |
| Ragazzoni, E | 1 |
| Rolandi, G | 1 |
| Finazzi, MC | 1 |
| Frewin, R | 1 |
| Dowson, A | 1 |
| Dua, V | 1 |
| Yadav, SP | 1 |
| Kumar, V | 1 |
| Saxena, R | 1 |
| Sachdeva, A | 1 |
| Dan, K | 1 |
| Troost, MM | 1 |
| van Genderen, PJ | 4 |
| Ruggeri, Z | 1 |
| Cannata, ML | 1 |
| Stella, NC | 1 |
| Corrado, F | 1 |
| Langer, C | 1 |
| Schafer, AI | 1 |
| Dutrillaux, F | 1 |
| Maynadié, M | 1 |
| Carli, PM | 1 |
| Elliott, MA | 2 |
| Niittyvuopio, R | 1 |
| Juvonen, E | 1 |
| Kaaja, R | 1 |
| Oksanen, K | 1 |
| Hallman, H | 1 |
| Timonen, T | 1 |
| Ruutu, T | 1 |
| East, CL | 1 |
| Bareford, D | 1 |
| van der Walt, JD | 1 |
| Reilly, JT | 2 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 1 |
| Costello, R | 1 |
| O'Callaghan, T | 1 |
| Sébahoun, G | 1 |
| Landolfi, R | 3 |
| Di Gennaro, L | 2 |
| Novarese, L | 1 |
| Petrides, PE | 2 |
| Yamaguchi, K | 1 |
| Hisano, M | 1 |
| Sakata, M | 1 |
| Minatogawa, Y | 1 |
| Suzuki, T | 1 |
| Ozawa, N | 1 |
| Kitagawa, M | 1 |
| Murashima, A | 1 |
| Budde, U | 2 |
| van Vliet, HH | 6 |
| Iwashita, T | 1 |
| Fujitani, M | 1 |
| Yamamoto, Y | 1 |
| Katsurada, T | 1 |
| Yoshida, Y | 1 |
| Koudstaal, PJ | 3 |
| Lindemans, J | 2 |
| Neumann, HA | 1 |
| Robins, EB | 1 |
| Niazi, M | 1 |
| Usukine, K | 1 |
| Shinhori, H | 1 |
| Idetsuki, T | 1 |
| Taoka, K | 1 |
| Nakasone, H | 1 |
| Kida, M | 1 |
| Iki, S | 1 |
| Urabe, M | 1 |
| Oseto, K | 1 |
| Igarashi, A | 1 |
| McLornan, D | 1 |
| McMullin, M | 1 |
| Cacciola, RR | 1 |
| Di Francesco, E | 1 |
| Pezzella, F | 1 |
| Tibullo, D | 1 |
| Giustolisi, R | 1 |
| Cacciola, E | 1 |
| Bellucci, S | 1 |
| Dinas, K | 1 |
| Hatzipantelis, E | 1 |
| Karasmanis, K | 1 |
| Zepiridis, L | 1 |
| Mavromatidis, G | 1 |
| Bontis, J | 1 |
| Flapper, B | 1 |
| Van Oostrom, C | 1 |
| de Vaan, G | 1 |
| Fröhli, P | 1 |
| Graf, C | 1 |
| Rhyner, K | 1 |
| Meschengieser, SS | 1 |
| Woods, AI | 1 |
| Schattner, MA | 1 |
| Lazzari, MA | 1 |
| Oswald, M | 1 |
| Beuers, U | 1 |
| Pape, GR | 1 |
| Paumgartner, G | 1 |
| Bauerschmitz, J | 1 |
| Knop, J | 1 |
| Fuse, I | 1 |
| Yamamoto, R | 1 |
| Hirahatake, K | 1 |
| Yamaguchi, M | 1 |
| Sato, C | 1 |
| van Strik, R | 2 |
| Mulder, AH | 1 |
| Oliveira, AS | 1 |
| Miranda, MP | 1 |
| Duarte, PC | 1 |
| Sarmento, JN | 1 |
| Pardini, S | 1 |
| Dore, F | 1 |
| Murineddu, M | 1 |
| Bontigli, S | 1 |
| Longinotti, M | 1 |
| Grigliotti, B | 1 |
| Spano, B | 1 |
| Nurden, P | 1 |
| Bihour, C | 1 |
| Smith, M | 1 |
| Raymond, JM | 1 |
| Nurden, AT | 1 |
| Yoshizumi, MO | 1 |
| Townsend-Pico, W | 1 |
| Delage, R | 1 |
| Demers, C | 1 |
| Cantin, G | 1 |
| Roy, J | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 3 |
| Guzzini, F | 1 |
| Ceppi, M | 1 |
| Gasparini, P | 1 |
| Sali, L | 1 |
| Vecchi, C | 1 |
| Eliyahu, S | 1 |
| Shalev, E | 1 |
| Koudstaal, A | 1 |
| Bangerter, M | 4 |
| Leenknegt, H | 1 |
| Cortelazzo, S | 2 |
| Orlando, E | 1 |
| Buchanan, MR | 1 |
| Willoughby, S | 1 |
| Rossi, C | 4 |
| Zerbinati, P | 1 |
| Rinaldi, V | 1 |
| Girolami, A | 4 |
| Luzzatto, G | 1 |
| Fabris, F | 4 |
| Knutsen, H | 1 |
| Bruserud, O | 1 |
| Beneke, H | 2 |
| Nussbaumer, B | 1 |
| Grünewald, M | 3 |
| Bergmann, L | 1 |
| Silverstein, MN | 1 |
| Menapace, L | 1 |
| Güthner, C | 1 |
| Hildebrand, A | 1 |
| Kudo, K | 1 |
| Horibe, K | 1 |
| Iwase, K | 1 |
| Kondo, M | 1 |
| Kojima, S | 1 |
| Blaser, T | 1 |
| Krueger, S | 1 |
| Kross, R | 1 |
| Lutze, G | 1 |
| Franke, A | 1 |
| Wieker, K | 1 |
| Goertler, M | 1 |
| Briere, J | 1 |
| Guilmin, F | 1 |
| Wright, CA | 1 |
| Vantroyen, B | 1 |
| Vanstraelen, D | 1 |
| Koh, LP | 1 |
| Devendra, K | 1 |
| Tien, SL | 1 |
| Vera, JC | 1 |
| Jeri, A | 1 |
| Horna, E | 1 |
| Rojas, M | 1 |
| Chow, EY | 1 |
| Haley, LP | 1 |
| Vickars, LM | 1 |
| Solal-Céligny, P | 1 |
| Fernandez, H | 1 |
| Tertian, G | 1 |
| Campbell, KM | 1 |
| Schubert, DS | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Pineo, GF | 1 |
| Blahey, WB | 1 |
| Beard, J | 1 |
| Hillmen, P | 1 |
| Anderson, CC | 1 |
| Lewis, SM | 1 |
| Chintagumpala, MM | 1 |
| Steuber, CP | 1 |
| Mahoney, DH | 1 |
| Ogden, AK | 1 |
| Fernbach, DJ | 1 |
| Bottaro, T | 1 |
| Cordì, GC | 1 |
| Gaggero, E | 1 |
| Motta, A | 1 |
| Venzano, C | 1 |
| Buelli, M | 1 |
| Viero, P | 1 |
| De Gaetano, G | 1 |
| Louwerenburg, JW | 1 |
| Suttorp, MJ | 1 |
| Herie Kingma, J | 1 |
| Falconer, J | 1 |
| Pineo, G | 1 |
| Blahey, W | 1 |
| Bowen, T | 1 |
| Docksteader, B | 1 |
| Jadusingh, I | 1 |
| Snethlage, W | 1 |
| Ten Cate, JW | 1 |
| Preston, FE | 1 |
| Emmanuel, IG | 1 |
| Winfield, DA | 1 |
| Malia, RG | 1 |
| Green, D | 1 |
| Rossi, EC | 1 |
| Geraud, J | 1 |
| Puel, P | 1 |
| Guiraud, B | 1 |
| Bris, J | 1 |
| Boneu, B | 1 |
| Gayrard, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838] | 1,398 participants (Actual) | Interventional | 1997-07-31 | Completed | |||
| French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study[NCT02611973] | Phase 3 | 2,250 participants (Anticipated) | Interventional | 2016-03-10 | Recruiting | ||
| Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms[NCT05850273] | 50 participants (Anticipated) | Observational | 2023-03-16 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
63 reviews available for aspirin and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.
Topics: Animals; Aspirin; Disease Management; Female; Humans; Phlebotomy; Platelet Aggregation Inhibitors; P | 2021 |
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quality of | 2022 |
Treatment options and pregnancy management for patients with PV and ET.
Topics: Aspirin; Female; Humans; Hydroxyurea; Janus Kinase 2; Janus Kinase Inhibitors; Myeloproliferative Di | 2022 |
Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
Topics: Aspirin; Blood Platelets; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prostaglandin-Endoper | 2023 |
BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Humans; Hydroxyurea; Mutation; Polycythemia Vera; Thrombocythemia, Essential | 2023 |
Essential Thrombocythemia.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Female; Humans; Megakaryocytes; Middle Aged; Mutatio | 2019 |
Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.
Topics: Adult; Antineoplastic Agents; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Male; | 2020 |
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Topics: Age Factors; Aspirin; Busulfan; Calreticulin; Disease-Free Survival; Humans; Interferon-alpha; Janus | 2020 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Platelet Count; Pregnan | 2018 |
Contemporary management of essential thrombocythemia in children.
Topics: Anticoagulants; Aspirin; Calreticulin; Child; Disease Management; Humans; Hydroxyurea; Interferon-al | 2019 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2013 |
Antiplatelet therapy in the management of myeloproliferative neoplasms.
Topics: Aspirin; Disease Management; Female; Humans; Male; Myeloproliferative Disorders; Platelet Aggregatio | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Topics: Aspirin; Diagnosis, Differential; Disease Management; Disease Progression; Humans; Janus Kinase 2; P | 2015 |
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
Topics: Aged; Aspirin; Calreticulin; Humans; Hydroxyurea; Janus Kinase 2; Livedo Reticularis; Male; Middle A | 2017 |
Pharmacotherapy of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Disease Progression; Humans; Hydroxyurea; Interferon-al | 2008 |
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia V | 2008 |
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polycythemi | 2008 |
Long-term management of thrombocytosis in essential thrombocythaemia.
Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interf | 2009 |
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Janus Kinase 2; Leukocytosis; Mutation; Platelet Aggregation Inhibitors; Polycythem | 2010 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Front-line therapy in polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Phlebotomy; Polycythemia Vera; Risk Factors; Thrombocythemia, Essential | 2012 |
Headache in essential thrombocythaemia.
Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders; | 2012 |
Pharmacotherapy of essential thrombocythaemia: economic considerations.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analys | 2003 |
Essential thrombocythemia.
Topics: Aspirin; Diagnosis, Differential; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; R | 2003 |
Thrombocytosis.
Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis | 2004 |
Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Hemostatics; Humans; Incidence; Platelet Activation; Platelet Aggregation; P | 2004 |
Pregnancy in essential thrombocythaemia: experience with 40 pregnancies.
Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Eclampsia; Female; Fetal Death; Finland; Humans; Pla | 2004 |
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb | 2005 |
[Treatment of essential thrombocythemia].
Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; | 2005 |
Essential thrombocythemia: scientific advances and current practice.
Topics: Antineoplastic Agents; Aspirin; Bone Marrow Examination; Humans; Hydroxyurea; In Situ Hybridization, | 2006 |
Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Platelet Activation; Polycythemia Vera; Thrombocythem | 2006 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, | 2006 |
Update on diagnosis and management of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhag | 2006 |
[Primary thrombocythemia: diagnosis and therapy].
Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; | 2006 |
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Blood Platelets; Deamino Arginine Vasopressin; Hemorrhage; Humans; Microcirc | 2006 |
How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
Topics: Aspirin; Evidence-Based Medicine; Humans; Hydroxyurea; Interferon-alpha; Ischemia; Janus Kinase 2; M | 2008 |
[Vascular complications of essential thrombocythemia].
Topics: Age Factors; Aspirin; Case-Control Studies; Controlled Clinical Trials as Topic; Humans; Middle Aged | 2007 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2008 |
Treatment of essential thrombocythemia during pregnancy with interferon-alpha.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Interferon-alpha; Male; Platelet Aggregation Inhibi | 1996 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Topics: Adult; Aged; Aspirin; Cyclooxygenase Inhibitors; Erythromelalgia; Female; Fibrinolytic Agents; Human | 1996 |
[Primary thrombocythemia in a female carrier of IgA deficiency].
Topics: Aged; Aspirin; Bacterial Vaccines; Biopsy; Bone Marrow; Chronic Disease; Combined Modality Therapy; | 1996 |
Essential thrombocythemia during pregnancy.
Topics: Adult; Anticoagulants; Aspirin; Dipyridamole; Female; Heparin; Humans; Platelet Aggregation Inhibito | 1997 |
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans; | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Topics: Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Polyc | 1998 |
[A management program for primary thrombocytopenia].
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Guidelines as Topic; Humans; Hydroxyurea; Interferon T | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
[Clinical features of essential thrombocythemia in three children].
Topics: Aspirin; Child; Dipyridamole; Female; Humans; Male; Thrombocythemia, Essential; Thrombopoietin | 2000 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
Current treatment practice for essential thrombocythaemia in adults.
Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thromboc | 2001 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature.
Topics: Abortion, Spontaneous; Aspirin; Blood Component Removal; Female; Fetal Death; Gestational Age; Human | 2002 |
[Pregnancy in patients with essential thrombocythemia. Three cases].
Topics: Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Count; Postpartum Period; Pr | 1992 |
Primary thrombocythaemia in pregnancy.
Topics: Abortion, Incomplete; Adult; Aspirin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologi | 1991 |
[Erythromelalgia and thrombotic thrombocythemia].
Topics: Aspirin; Erythromelalgia; Humans; Thrombocythemia, Essential | 1989 |
Disorders of platelet function.
Topics: Adenosine Diphosphate; Adolescent; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; | 1972 |
15 trials available for aspirin and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Topics: Adult; Aged; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Double-Blind Method; Epoprostenol | 2020 |
'MPN Genomic Calculator': real-life use in a young population with essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Female; Genomics; Humans; Male; Middle Aged; Mutation; Thrombocythemia, Essent | 2020 |
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B
Topics: Aspirin; Biomarkers; Clinical Protocols; Disease Management; Female; Humans; Male; Patient Selection | 2018 |
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2018 |
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Blood Platelets; Clinical Protocols; Drug Dosage Calcul | 2014 |
The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.
Topics: Aspirin; Biomarkers; Female; Hematologic Neoplasms; Humans; Janus Kinase 2; Male; Middle Aged; Nitri | 2015 |
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Cell Com | 2009 |
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.
Topics: Adult; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Therapy, Combina | 2010 |
Neurological disorders in essential thrombocythemia.
Topics: Amino Acid Substitution; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; H | 2011 |
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.
Topics: Acceleration; Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Over | 2012 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada | 2007 |
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Topics: Adult; Aged; Aspirin; Cyclooxygenase Inhibitors; Erythromelalgia; Female; Fibrinolytic Agents; Human | 1996 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
109 other studies available for aspirin and Hemorrhagic Thrombocythemia
| Article | Year |
|---|---|
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.
Topics: Aspirin; Cytoreduction Surgical Procedures; Humans; Platelet Aggregation Inhibitors; Platelet Count; | 2022 |
[Idiopathic esophageal submucosal hematoma during antithrombotic therapy for essential thrombocythemia].
Topics: Aged; Aspirin; Chest Pain; Esophageal Diseases; Female; Fibrinolytic Agents; Gastrointestinal Hemorr | 2022 |
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es | 2022 |
Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia.
Topics: Aspirin; Blood Platelets; Humans; Hydroxyurea; Platelet Aggregation; Platelet Function Tests; Thromb | 2022 |
Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Topics: Aspirin; Humans; Prognosis; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombo | 2022 |
Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing.
Topics: Aspirin; Blood Platelets; Humans; Models, Theoretical; Obesity; Platelet Aggregation Inhibitors; Thr | 2022 |
Anagrelide with low-dose aspirin promptly epithelized ulceronecrotic lesion secondary to essential thrombocythemia.
Topics: Aspirin; Bone Marrow; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kin | 2020 |
Essential Thrombocythemia.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombocythemia, Essential | 2020 |
Essential Thrombocythemia.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombocythemia, Essential | 2020 |
Essential Thrombocythemia. Reply.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombocythemia, Essential | 2020 |
Limb gangrene: The first sign of essential thrombocythemia.
Topics: Aged, 80 and over; Amputation, Surgical; Aspirin; Female; Gangrene; Humans; Hydroxyurea; Leg; Platel | 2020 |
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; | 2020 |
Aspirin in ET: will twice a day keep thrombosis away?
Topics: Aspirin; Double-Blind Method; Humans; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; T | 2020 |
Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety.
Topics: Abortion, Spontaneous; Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Interferon-alp | 2021 |
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Topics: Adult; Aspirin; Blood Platelets; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Mutation; M | 2020 |
Multiple aortic thrombi in essential thrombocythaemia.
Topics: Aged; Aorta, Abdominal; Aspirin; Cefazolin; Echocardiography; Heparin; Humans; Hydroxyurea; Male; St | 2021 |
Acetylsalicylic acid in essential thrombocythemia.
Topics: Aspirin; Humans; Thrombocythemia, Essential | 2022 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethas | 2021 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Essential Thrombocytosis and Labor Epidural Placement While on Aspirin: Assessing Hemorrhagic Risks: A Case Report.
Topics: Adult; Anesthesia, Epidural; Aspirin; Bupivacaine; Female; Fentanyl; Humans; Labor, Obstetric; Lidoc | 2017 |
Painful Erythematous-violaceous Toe: A Quiz.
Topics: Aged; Aspirin; Blue Toe Syndrome; Erythema; Female; Humans; Pain; Platelet Aggregation Inhibitors; S | 2018 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans | 2013 |
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therap | 2013 |
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment.
Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors | 2013 |
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Jan | 2013 |
[A preschool child with primary thrombocytosis].
Topics: Aspirin; Blood Cell Count; Blood Platelets; C-Reactive Protein; Child, Preschool; Diagnosis, Differe | 2013 |
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aspirin; Cerebral Cortex; Erythromelalgia; Eye; Female; Follow-Up Studies; Humans; Isch | 2015 |
New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
Topics: Age Factors; Aged; Aspirin; Drug Administration Schedule; Enzyme Inhibitors; Fibrinolytic Agents; Hu | 2015 |
Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Aged; Amyloid Precursor Protein Secretases; Aspirin; | 2015 |
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Topics: Adolescent; Adult; Alleles; Aspirin; Calreticulin; Clonal Evolution; Clone Cells; Dioxygenases; DNA | 2015 |
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
Topics: Aspirin; Humans; Janus Kinase 2; Mutation; Risk Factors; Thrombocythemia, Essential; Thrombosis; Wor | 2015 |
Postpartum haemorrhage in a woman with essential thrombocythemia carrying calreticulin mutation: a case report.
Topics: Adult; Aspirin; Calreticulin; Female; Fibrinolytic Agents; Humans; Mutation; Postpartum Hemorrhage; | 2016 |
Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: A case report.
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; T | 2016 |
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus | 2016 |
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Human | 2017 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.
Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; E | 2017 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrino | 2009 |
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.
Topics: Abortion, Spontaneous; Adolescent; Adult; Aspirin; Female; Humans; Janus Kinase 2; Leukocyte Count; | 2009 |
[Intradural block in essential thrombocytosis].
Topics: Aged, 80 and over; Anesthesia, Spinal; Aspirin; Female; Fracture Fixation, Internal; Hematoma, Epidu | 2009 |
Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Interferon Type I; Italy; Janus Kinase 2; Middle Aged; M | 2009 |
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu | 2009 |
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon Type I; Pregnancy; P | 2009 |
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies.
Topics: Aspirin; Female; Genotype; Humans; Janus Kinase 2; Mutation; Phenotype; Platelet Aggregation Inhibit | 2010 |
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythr | 2009 |
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Austria; Case-Control Studies; Clopid | 2010 |
Aspirin in low-risk essential thrombocythemia, not so simple after all?
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Prognosis; Thrombocythemia, Essential | 2011 |
Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Comorbidity; Humans; Hydroxyurea; Janus Kinase | 2012 |
[Pregnancy and essential thrombocytemia].
Topics: Adult; Aspirin; Female; Hospitals, University; Humans; Platelet Aggregation Inhibitors; Pregnancy; P | 2011 |
Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Epinephrine; Female; Greece; Human | 2011 |
Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia.
Topics: Aged; Arachidonic Acid; Aspirin; Drug Administration Schedule; Drug Resistance; Female; Humans; Male | 2012 |
Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
Topics: Alkylating Agents; Anticoagulants; Aspirin; CD146 Antigen; Drug Therapy, Combination; E-Selectin; En | 2012 |
Overcoming "aspirin resistance" in MPN.
Topics: Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Female; Humans; Male; Thrombocythemia, Essential; Throm | 2012 |
Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
Topics: Aspirin; Asymptomatic Diseases; Bone Marrow; Child; Child, Preschool; Female; Headache; Humans; Hydr | 2012 |
[Essential thrombocythemia: molecular pathophysiology and treatment].
Topics: Aspirin; Humans; Janus Kinase 2; Mutation; Thrombocythemia, Essential | 2012 |
Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA-100.
Topics: Adult; Aged; Aspirin; Bleeding Time; Female; Hemostasis; Humans; Male; Middle Aged; Platelet Functio | 2002 |
Pregnancy in essential thrombocythemia during aspirin treatment.
Topics: Adult; Aspirin; Cesarean Section; Drug Administration Schedule; Female; Humans; Infant, Newborn; Mal | 2003 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Thrombocythemia, Es | 2004 |
Essential thrombocythaemia in children: is a treatment needed?
Topics: Adult; Aspirin; Child; Clinical Trials, Phase II as Topic; Humans; Interferon-alpha; Quinazolines; T | 2004 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
Periodic plateletpheresis during pregnancy in a high-risk patient with essential thrombocythemia.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Blood Flow Velocity; Cesarean Section; Female | 2006 |
The use of aspirin and clinical implications in essential thrombocythemia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Humans; Middle Aged; Platel | 2006 |
Interferon-alfa treatment of essential thrombocythemia during pregnancy.
Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Diseases; Humans; Immunolog | 2006 |
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
Topics: Aged; Anticoagulants; Aspirin; Drug Resistance; Erythromelalgia; Female; Humans; Ischemia; Male; Mic | 2006 |
Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies.
Topics: Aspirin; Bone and Bones; Child, Preschool; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Male; Mot | 2008 |
[Case of erythromelalgia due to essential thrombocythemia].
Topics: Aged; Aspirin; Debridement; Diagnosis, Differential; Erythromelalgia; Female; Humans; Hydroxyurea; T | 2007 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
Improving the outcome of pregnancy in essential thrombocythaemia: The role of aspirin.
Topics: Adult; Aspirin; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, | 2008 |
[Primary thrombocythemia in childhood].
Topics: Adolescent; Aspirin; Child; Dipyridamole; Drug Therapy, Combination; Female; Humans; Male; Melphalan | 1983 |
[Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Polycythemia Ver | 1983 |
[Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Topics: Adult; Aspirin; Blood Platelet Disorders; Dipyridamole; Female; Humans; Leukemia, Myeloid; Male; Mid | 1981 |
[23-year-old patient with abdominal pain, hepatosplenomegaly, ascites and leg edema].
Topics: Adult; Ascites; Aspirin; Biopsy; Blood Coagulation Tests; Budd-Chiari Syndrome; Combined Modality Th | 1995 |
[Cutaneous manifestations of essential thrombocythemia. Erythromelalgia, ischemic acrocyanosis, livedo racemosa].
Topics: Aged; Aspirin; Cyanosis; Diagnosis, Differential; Erythromelalgia; Female; Humans; Ischemia; Skin; T | 1995 |
[Recent trends in therapy of chronic myeloproliferative disorders].
Topics: Alkylating Agents; Aspirin; Humans; Hydroxyurea; Interferons; Pipobroman; Prognosis; Thrombocythemia | 1993 |
[A case of pregnancy with essential thrombocythemia].
Topics: Adult; Aspirin; Dipyridamole; Female; Heparin; Humans; Pregnancy; Pregnancy Complications, Hematolog | 1995 |
Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin.
Topics: Adult; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Survival; Erythromelalgia; Female; | 1995 |
Transient neurologic and ocular manifestations in primary thrombocythemia.
Topics: Adult; Aged; Aspirin; Eye Diseases; Female; Humans; Male; Middle Aged; Nervous System Diseases; Plat | 1993 |
[Essential thrombocythemia. Apropos a case of cerebrovascular stroke].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; | 1993 |
Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Infarction; Interferon alpha-2; Interferon-alpha; P | 1993 |
Platelet activation and thrombosis: studies in a patient with essential thrombocythemia.
Topics: Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Blood Platelets; Disease Susceptibili | 1996 |
Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma.
Topics: Adrenergic beta-Antagonists; Antisickling Agents; Aspirin; Bone Marrow; Fluorescein Angiography; Fun | 1996 |
The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Humans; Male; Middle Aged; Platelet Count; Thromboc | 1996 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Aspirin; Bleeding Time; Blood Coagulation; Humans; Lipox | 1998 |
Acute coronary disease in essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aging; Antisickling Agents; Aspirin; Female; Follow-Up Studies; Humans; Hydroxyurea; Ma | 1998 |
Low-risk essential thrombocythaemia in patients younger than 40.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; | 1999 |
Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies.
Topics: Adult; Aspirin; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, | 1999 |
Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia.
Topics: Aspirin; Blood Platelets; Flow Cytometry; Gene Expression Regulation; Humans; Middle Aged; P-Selecti | 1999 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.
Topics: Abortion, Spontaneous; Adult; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pl | 2000 |
Acetylsalicylic acid induced cessation of transient ischaemic attacks and microembolic signals detected by transcranial Doppler in a patient with essential thrombocythaemia.
Topics: Administration, Oral; Aged; Aspirin; Fibrinolytic Agents; Humans; Infusions, Intravenous; Intracrani | 2001 |
Four pregnancies in two patients with essential thrombocythaemia--a case report.
Topics: Adult; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Female; Fetal Death; Humans; H | 2002 |
Antiplatelet agents in the treatment of thrombotic complications of primary thrombocythemia.
Topics: Aged; Aspirin; Humans; Male; Sulfinpyrazone; Thrombocythemia, Essential; Thrombosis | 1979 |
[Essential thrombocytosis. Presentation of one case (author's transl)].
Topics: Adult; Aspirin; Busulfan; Humans; Male; Thrombocythemia, Essential | 1975 |
Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome.
Topics: Adult; Aspirin; Female; Humans; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pre | 1992 |
Reversal of delirium associated with essential thrombocythemia by antiplatelet therapy.
Topics: Aged; Aspirin; Delirium; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Coun | 1992 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
Erythromelalgia versus erythermalgia.
Topics: Aspirin; Erythromelalgia; Humans; Raynaud Disease; Thrombocythemia, Essential | 1990 |
Essential thrombocythemia and complications of pregnancy.
Topics: Abortion, Incomplete; Aspirin; Female; Fetal Death; Humans; Pregnancy; Pregnancy Complications, Hema | 1991 |
Essential thrombocythemia in a child: management with anagrelide.
Topics: Aspirin; Child; Drug Therapy, Combination; Humans; Male; Platelet Aggregation Inhibitors; Platelet C | 1991 |
[Essential thrombocythemia. Case reports and clinico-therapeutic considerations].
Topics: Alkylating Agents; Antimetabolites; Aspirin; Bone Marrow; Dipyridamole; Drug Therapy, Combination; H | 1990 |
Aspirin and risk of bleeding in patients with thrombocythemia.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adolescent; Adult; Aged; Aspirin; Bleeding Time; Blood P | 1987 |
Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Su | 1987 |
Essential thrombocythemia associated with recurrent abortions and fetal growth retardation.
Topics: Abortion, Habitual; Adult; Aspirin; Dipyridamole; Female; Fetal Growth Retardation; Humans; Platelet | 1987 |
Thrombocythaemia and recurrent late abortions: normal outcome of pregnancies after antiaggregatory treatment. Case report.
Topics: Abortion, Habitual; Adult; Aspirin; Dipyridamole; Female; Humans; Pregnancy; Pregnancy Trimester, Se | 1986 |
Essential thrombocythaemia and peripheral gangrene.
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Cell Count; Collagen; Gangrene; Humans; Male; Middle Ag | 1974 |
[Action of Aspirin on the vascular manifestations of thrombocythemia].
Topics: Aspirin; Blood Platelet Disorders; Epinephrine; Humans; Male; Platelet Adhesiveness; Thrombocythemia | 1972 |